Loading company
ONCBeone Medicines Ltd.$48BA+Built from Benitec Biopharma Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
The themes Benitec Biopharma is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
$9.45+1.7%Nov 11 close
Reported results on November 13, 2026; they are not in these figures yet.
Next earnings: November 13, 2026
Figures through June 30, 2026, from the 10-K filed September 14, 2026
Grade D
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 23 quarters of Benitec Biopharma Inc.’s grade history. The other 21 go back to February 2021.
